AcelRx Pharmaceuticals (ACRX) Scheduled to Post Earnings on Monday

AcelRx Pharmaceuticals (NASDAQ:ACRXGet Rating) is set to post its quarterly earnings results after the market closes on Monday, November 14th. Analysts expect AcelRx Pharmaceuticals to post earnings of ($1.20) per share for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

AcelRx Pharmaceuticals (NASDAQ:ACRXGet Rating) last released its earnings results on Thursday, August 11th. The specialty pharmaceutical company reported ($1.20) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.20). The firm had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.60 million. During the same period in the prior year, the business earned ($1.60) earnings per share. On average, analysts expect AcelRx Pharmaceuticals to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

AcelRx Pharmaceuticals Price Performance

NASDAQ:ACRX opened at $2.06 on Friday. The company has a market capitalization of $15.18 million, a P/E ratio of 0.35 and a beta of 0.29. AcelRx Pharmaceuticals has a 1 year low of $1.76 and a 1 year high of $16.56. The business has a fifty day simple moving average of $5.55 and a two-hundred day simple moving average of $5.10.

Hedge Funds Weigh In On AcelRx Pharmaceuticals

An institutional investor recently bought a new position in AcelRx Pharmaceuticals stock. Virtu Financial LLC purchased a new position in shares of AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRXGet Rating) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 119,460 shares of the specialty pharmaceutical company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.08% of AcelRx Pharmaceuticals as of its most recent SEC filing. Hedge funds and other institutional investors own 11.61% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on AcelRx Pharmaceuticals in a research report on Friday, October 28th. They issued a “hold” rating for the company.

AcelRx Pharmaceuticals Company Profile

(Get Rating)

AcelRx Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures.

See Also

Earnings History for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.